|Organic compounds -- part of the class 532-570 series patents - Monitor Patents|
USPTO Class 536 | Browse by Industry: Previous - Next | All
Recent | 13: May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Organic compounds -- part of the class 532-570 seriesBelow are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 05/16/2013 > 13 patent applications in 9 patent subcategories.
20130123477 - Tiacumicin production: Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species Dactylosporangium aurantiacum subspecies hamdenensis having the ability to produce and accumulate one or more Tiacumicin in a nutrient medium comprising a carbon source, a nitrogen source, trace elements such as... Agent: Optimer Pharmaceuticals, Inc.
20130123478 - Methods of preparing targeted aptamer prodrugs: The present invention provides methods of preparing an oligonucleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells, the method comprising (1) selecting a targeted aptamer, internalizing nucleic acid or tumor-homing nucleic acid via iterative rounds of selection, and (i) hybridizing it to an oligonucleotide, (ii) replacing one... Agent:
20130123481 - Modified nucleosides, nucleotides, and nucleic acids, and uses thereof: The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.... Agent: Moderna Therapeutics
20130123480 - Multicomponent nucleic acid enzymes and methods for their use: The present invention relates to Multicomponent Nucleic Acid Enzymes (MNAzymes) and methods for their use. MNAzymes comprise two or more oligonucleotide components which self-assemble in the presence of one or more MNAzyme assembly facilitator molecules to form a catalytically active structure. Compositions for making MNAzymes, and collections of MNAzymes are... Agent: Speedx Pty Ltd
20130123482 - Nucleotide and/or oligonucleotide and preparation process thereof: Nucleotide and/or oligonucleotide represented by formula (1) and the liquid phase synthesis process thereof. The present invention provides a liquid phase synthesis process for preparing a nucleotide and/or an oligonucleotide, comprising a process for combining the nucleotide and/or oligonucleotide protective groups, in which, under the condition that the 2′-hydroxyl group... Agent: Suzhou Ribo Life Science Co., Ltd
20130123479 - Soluble tnf receptors and their use in treatment of disease: The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular,... Agent:
20130123483 - Method and device for optimizing a nucelotide sequence for the purpose of expression in a protein: The invention relates to a method for optimizing a nucleotide sequence for expression of a protein on the basis of the amino acid sequence of the protein, in which for a particular region there is specification of a test sequence with m optimization positions on which the codon occupation is... Agent: Geneart Ag
20130123484 - Position dependent recognition of gnn nucleotide triplets by zinc fingers: The specificity of binding of a zinc finger to a triplet or quadruplet nucleotide target subsite depends upon the location of the zinc finger in a multifinger protein and, hence, upon the location of its target subsite within a larger target sequence. The present disclosure provides zinc finger amino acid... Agent: Sangamo Biosciences, Inc.
20130123485 - Cationic lipids, methods for preparing the same, and delivery systems having ability to transition into cells comprising the same: The present invention provides cationic lipids, methods for preparing the same, and delivery systems comprising the same. The present invention can provide cationic lipids which enhance the efficiency of intracellular or in vivo delivery of multiple-anionic target compounds such as drugs, anticancer agents, nucleic acids, etc., have no intracellular toxicity,... Agent:
20130123486 - Photogenerated reagents: This invention describes reagent precursors and methods for chemical and biochemical reactions. These reagent precursors that can be activated in solution upon irradiation to generate reagents required for the subsequent chemical reactions. Specifically, photogenerated reagents (PGR) are useful for controlling parallel combinatorial synthesis and various chemical and biochemical reactions.... Agent:
20130123487 - Controlled release from solid supports: The invention relates to solid supports useful in medical applications that provide controlled release of drugs, such as peptides, nucleic acids and small molecules. The drugs are covalently coupled to the solid support through a linkage that releases the drug or a prodrug through controlled beta elimination.... Agent: Prolynx LLC
20130123488 - Guar gum containing compounds: e
20130123489 - Process for removing divalent cations from milk by-products: A process for removing divalent cations, such as magnesium and calcium, from milk by-products, such as whey from cheese making and whey by-products from membrane processes, wherein the weak cationic resin is in the alkali form.... Agent:05/09/2013 > 12 patent applications in 9 patent subcategories.
20130116416 - Ketoreductase mutant: Disclosed are a ketoreductase mutant which can be used for an efficient production of daunorubicin derivatives, a DNA encoding the mutant, a transformant prepared by introducing the DNA thereinto to produce a daunorubicin derivative, and a process of producing a daunorubicin derivative using the transformant. The ketoreductase mutant has an... Agent: Meiji Seika Pharma, Co., Ltd.
20130116417 - Methods for the development of vaccines based on oligosaccharide-oligonucleotide conjugates: Described herein are oligosaccharide-oligonucleotide conjugates useful as vaccines against one or more human or veterinary therapeutic indications, and methods of synthesizing and identifying them. The conjugates may be identified using non-human antibodies as binding targets, thereby expanding the power and scope of the invention. Efficacious conjugates may be identified through... Agent: Brandeis University
20130116420 - 5' modified nucleosides and oligomeric compounds prepared therefrom: The present invention provides 5′ modified nucleosides and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides having at least one 5′-substituent and an optional 2′ substituent, oligomeric compounds comprising at least one of these modified nucleosides and methods of using the oligomeric compounds. In some embodiments,... Agent: Isis Pharmaceuticals, Inc.
20130116419 - Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via \"click\" chemistry: This invention relates to the post-synthetic chemical modification of RNA at the 2′-position on the ribose ring via a copper catalyzed Huisgen cycloaddition (“click” chemistry: Kolb, Sharpless Drug Discovery Today 2003, 8, 1128). The invention 1) avoids complex, tedious multi-step syntheses of each desired modified ribonucleoside; 2) allows diverse chemical... Agent:
20130116421 - Method for producing unsaturated omega-3-fatty acids in transgenic organisms: The present invention relates to nucleic acid sequences coding for polypeptides with ω-3-desaturase activity. The invention furthermore relates to nucleic acid constructs, vectors and organisms comprising at least one nucleic acid sequence according to the invention, at least one vector comprising the nucleic acid sequence and/or the nucleic acid constructs,... Agent: Basf Plant Science Gmbh
20130116422 - Dendritic starch-based dextrin adhesives: Starch-based dextrin adhesive additives and methods of preparation are described. Adhesives containing the additive exhibit antimicrobial properties and increased water solubility. The additive contains at least one sugar unit, at least one polyphenol side chain, and at least one Frechet-type poly(aryl ether)dendron.... Agent: Empire Technology Development LLC
20130116423 - Synthetic oligosaccharides for staphylococcus vaccine: The present invention synthetic oligo-β-(1→6)-glucosamine structures and a methodology which essentially allows for the synthesis of any oligo-β-(1→6)-glucosamine species having a definite number of monosaccharide units, including a set pattern of acetylated and non-acetylated residues. The invention further provides antibodies to these synthetic oligo-β-(1→6)-glucosamines as well as compositions thereof and... Agent:
20130116424 - Method for producing biobased chemicals from plant biomass: A method for utilizing biomass components, namely cellulose, hemicellose, and lignin, and converting them to value-added biobased chemical products is described herein. The present method provides treatments to obtain a plurality of component streams from biomass for producing derivative products while minimizing waste products.... Agent: Thesis Chemistry, LLC
20130116425 - Cellulose interpolymers and method of oxidation: This invention provides cellulose ester interpolymers, and methods of oxidizing cellulose interpolymers and cellulose ester interpolymers. The invention also provides routes to access carboxylated cellulose ester derivatives with high acid numbers wherein the carboxyl group is attached directly to the cellulose backbone by a carbon-carbon bond. Through functionalization of an... Agent: Eastman Chemical Company
20130116426 - Cellulose interpolymers and method of oxidation: This invention provides cellulose ester interpolymers, and methods of oxidizing cellulose interpolymers and cellulose ester interpolymers. The invention also provides routes to access carboxylated cellulose ester derivatives with high acid numbers wherein the carboxyl group is attached directly to the cellulose backbone by a carbon-carbon bond. Through functionalization of an... Agent: Eastman Chemical Company
20130116427 - Cellulose interpolymers and method of oxidation: This invention provides cellulose ester interpolymers, and methods of oxidizing cellulose interpolymers and cellulose ester interpolymers. The invention also provides routes to access carboxylated cellulose ester derivatives with high acid numbers wherein the carboxyl group is attached directly to the cellulose backbone by a carbon-carbon bond. Through functionalization of an... Agent: Eastman Chemical Company05/02/2013 > 3 patent applications in 2 patent subcategories.
20130109848 - Multidimensional supramolecular structures essentially made of assembled i-motif tetramers: The present invention pertains to a supramolecular structure based on i-motif tetramers of Cm—X—Cn oligonucleotides, wherein m and n are integers comprised between 2 and 9, and X is a linker such as A, T, G, a modified deoxynucleotide or a diol spacer. These supramolecular structures can be dissociated, when... Agent: Centre National De La Recherche Scientifique
20130109849 - Compositions and their uses directed to aceytl-coa carboxylases: Disclosed herein are compounds, compositions and methods for modulating the expression of ACC1 or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.... Agent: Isis Pharmaceuticals, Inc.
20130109850 - Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom: Provided herein are modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom. More particularly, modified 5′ diphosphate nucleosides are provided that can be further modified at the 2′ and 5′ positions. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA... Agent: Isis Pharmaceuticals, Inc04/25/2013 > 10 patent applications in 9 patent subcategories.
20130102764 - Process for perparing fondaparinux sodium and intermediates useful in the synthesis thereof: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation... Agent: Reliable Biopharmaceutical Corporation
20130102765 - Novel glyphosate-n-acetyltransferase (gat) genes: Novel proteins are provided herein, including proteins capable of catalyzing the acetylation of glyphosate and other structurally related proteins. Also provided are novel polynucleotides capable of encoding these proteins, compositions that include one or more of these novel proteins and/or polynucleotides, recombinant cells and transgenic plants comprising these novel compounds,... Agent: Pioneer Hi-bred International, Inc.
20130102766 - Method and compositions for monitoring dna binding molecules in living cells: The present invention provides a method of screening for a compound that binds to a selected nucleic acid comprising contacting compound fluorescently labeled by a fluorescent protein with a cell having a plurality of copies of the nucleic acid in an array such that the nucleic acid can be directly... Agent:
20130102767 - Nucleic acid sequences encoding strictosidine synthase proteins: Isolated polynucleotides and polypeptides encoded thereby are described, together with the use of those products for making transgenic plants.... Agent:
20130102768 - Efficient method for nuclear reprogramming: A method of preparing induced pluripotent stem cells, comprising a nuclear reprogramming step with a nuclear reprogramming factor in the presence of miRNA, wherein said miRNA has a property of providing a higher nuclear reprogramming efficiency in the presence of said miRNA than in the absence thereof.... Agent: Kyoto University
20130102769 - Interfering rna molecules: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target... Agent: Silence Therapeutics Aktiengesell Schaft (ag)
20130102770 - Metal enhanced fluorescence-based sensing methods: The present invention relates to metallic-surface detection systems for determining target substances including free bilirubin in neonatal serum in the presence of a predominantly high background of bilirubin bound Human Serum Albumin (HSA) or sensing and isolating target nucleotide sequences wherein a fluorescence signal is enhanced by close proximity of... Agent:
20130102771 - Neurite outgrowth agent: An object of the present invention is to provide a non-peptidic nerve axon and/or neurite outgrowth agent for allowing a nerve axon and a neurite to elongate. 3-(Aminocarbonyl)-1-[5-O-[[1-(6-amino-9H-purin-9-yl)-1-deoxy-β-D-ribofuranos-5-O-yl]phosphonyloxy(oxylato)phosphinyl]-β-L-ribofuranosyl]pyridinium that is an analogue of nicotinamide adenine dinucleotide (NAD) comprising β-L-ribose as the sugar component is used as a nerve axon and/or... Agent: Hidenori Kaminishi
20130102772 - Systems, methods and devices for producing, manufacturing and control of radiopharmaceuticals-full: Systems, methods, and devices for generating radionuclides for use in production of radiopharmaceuticals; synthesizing the radionuclides generated and removing any unwanted products; measuring the quantity and activity level of the synthesized radionuclides; distributively delivering the radionuclides in appropriate quantities to modular cassette synthesis units in a modular cassette subsystem for... Agent: Cardinal Health 414, LLC
20130102773 - Method of preparing sucralose-6-ester by catalysis and chlorination of phase transfer catalyst: A method of preparing sucralose-6-ester by catalysis and chlorination of phase transfer catalyst comprises the following steps: add phase transfer catalyst into a prepared Vilsmeier reagent and then drip in DMF solution of sucrose-6-ester at 5-10° C. to obtain a feed solution and after that maintain its temperature of the... Agent: Hubei Yitai Pharmaceutical Co.,ltd.Previous industry: Organic compounds -- part of the class 532-570 series
Next industry: Organic compounds -- part of the class 532-570 series
RSS FEED for 20130516:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Organic compounds -- part of the class 532-570 series patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Organic compounds -- part of the class 532-570 series patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Organic compounds -- part of the class 532-570 series patents we recommend signing up for free keyword monitoring by email.
FreshPatents.com Support - Terms & Conditions
Results in 0.20634 seconds